Paclitaxel induces apoptosis of esophageal squamous cell carcinoma cells by downregulating STAT3 phosphorylation at Ser727

XIAOLONG ZHANG1,2*, XIAOYI WU2*, FANGLING ZHANG3*, SHOUYONG MO2,4, YUANYUAN LU2, WEI WEI2, XIAOLING CHEN2, LINHUA LAN2, BIN LU2 and YONGZHANG LIU2

1Department of Anesthesia and Critical Care, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027; 2Protein Quality Control and Diseases Laboratory, Cancer Center, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University; 3The Second Clinical Medical School, Wenzhou Medical University, Wenzhou, Zhejiang 325035; 4The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 323000, P.R. China

Received September 26, 2016; Accepted March 7, 2017

DOI: 10.3892/or.2017.5503

Correspondence to: Professor Bin Lu or Professor Yongzhang Liu, Protein Quality Control and Diseases Laboratory, Cancer Center, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
E-mail: lubmito@wmu.edu.cn
E-mail: lyz@wmu.edu.cn

*Contributed equally

Key words: paclitaxel, esophageal squamous cell carcinoma, STAT3, apoptosis, mitochondria

Abstract. Paclitaxel induces apoptosis in a variety of cancer cells. However, the mechanism of paclitaxel inducing apoptosis in human esophageal squamous cell carcinoma (ESCC) remains to be defined. In this study, we found that paclitaxel-induced apoptosis by increasing the relevant apoptosis protein expression and the release of cytochrome c via downregulation of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 (Ser727). In addition, paclitaxel treatment of ESCC cells EC-1 and Eca-109 led to marked mitochondrial membrane potential depolarization and significantly increasing of reactive oxygen species. Moreover, paclitaxel treatment resulted in the inhibition of mitochondrial respiration. In conclusion, our findings reveal that paclitaxel induced apoptosis in both EC-1 and Eca-109 cells through the reduction of STAT3 and phospho-STAT3 (Ser727) level, and suggest that paclitaxel may be of therapeutic potential in the treatment of ESCC through the induction of mitochondrial apoptosis in ESCC cells.

Introduction

Esophageal cancer is one of the most common and aggressive types of cancer worldwide, it is ranked as the 8th in morbidity and 6th in cancer-related mortality (1,2). Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EA) are the two major histological types of esophageal cancer (3). However, ESCC is the main subtype of esophageal cancer and comprises ~70% of cases worldwide (4,5). The incidence of ESCC has been increasing steadily in high-incidence areas such as northern China, Iran and South Africa (4-6), and the overall survival still remains extremely poor due to lack of effective biomarkers for early diagnosis, and therapeutic target. Therefore, a better understanding of the mechanism of this malignancy to identify and characterize novel therapies is definitely necessary and of great urgency.

Paclitaxel is a cytotoxic apoptosis inducer and antineoplastic drug against a broad-spectrum of cancers such as ovarian cancer, lung cancer, breast cancer and melanoma (7). As a single agent, paclitaxel has been shown to have a response rate of 32% in esophageal cancer (8). In addition, several phase II studies indicated that paclitaxel-based regimens play an important role in patients with locally advanced and metastatic esophageal cancer (9-11). Moreover, paclitaxel may increase the sensitivity of tumor cells to radiation (12-14). Signal transducers and activators of transcription 3 (STAT3) involved in cell proliferation, differentiation, cell survival and death in response to various signaling through the phosphorylation and nuclear translocation (15,16). STAT3 was constitutively activated in cancer tissues of ESCC (17). Wegrzyn et al found that STAT3 may translocate to mitochondria, and the mitochondrial STAT3 (mtSTAT3) is important for the functions of mitochondrial electron transport chain (ETC) since the activities of complex I and II of mitochondrial ETC were significantly decreased in STAT3−/− cells (18). Moreover, mtSTAT3 supports Ras-dependent malignant transformation by regulating the glycolysis and oxidative phosphorylation (OXPHOS) of cancer cells (19). Previous studies on paclitaxel-induced apoptosis mainly focused on the mitochondrial apoptotic pathways (20-22). However, the regulatory mechanism of
how it induces apoptosis and the role of STAT3 in ESCC cells remains to be further investigated.

Materials and methods

Reagents and antibodies. Paclitaxel was obtained from Sangon Biotech Co. (Shanghai, China). Horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-mouse immunoglobulin G, MTT Cell Proliferation and Cytotoxicity Assay kit, ROS Assay kit (DCFH-DA) and mitochondrial membrane potential (MMP) Assay kit (JC-1) were all obtained from Beyotime Biotech (Jiangsu, China). Annexin V-Fluorescein Isothiocyanate (FITC) Apoptosis Detection kit was obtained from BD Biosciences (Franklin Lakes, NJ, USA). BCA Protein Assay kit and Pierce ECL Western Blotting Substrate were both obtained from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Monoclonal antibody against β-actin was from Abmart (Shanghai, China). Polyclonal antibody against PARP, caspase-3, cleaved caspase-3, caspase-7, cleaved caspase-7, caspase-9, cleaved caspase-9, STAT3, phospho-STAT3 (Ser727) were all obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA). Polyclonal antibody against cytochrome c, COX IV, GAPDH, VDAC were all purchased from Abcam (Cambridge, UK).

Cell lines and cell culture. The ESCC cell lines, EC-1 and Eca-109 were both purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (both from Invitrogen, Carlsbad, CA, USA) and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) at 37°C in a humidified atmosphere of 5% CO₂.

Isolation of cytoplasmic and mitochondrial fractions. EC-1 and Eca-109 cells were treated with 12 and 20 nM paclitaxel for 24 h, respectively. The cells were harvested in 2 ml 0.1X isolation buffer (IB: 3.5 mM Tris-HCl, 2.5 mM NaCl, 0.5 mM MgCl₂ and protease inhibitors, pH 7.8) and incubated on ice for 2 min. The mixture was then transferred into the Dounce glass homogenizer. After more than 90% of cells were confirmed to be broken by using phase contrast microscopy, 200 µl 10X IB and 0.1X IB were added into the mixture for further lysing the cells. The lysate were then centrifuged at 1,000 x g for 3 min, and the supernatant was transferred to a new Eppendorf tube, centrifuged at 15,000 x g for 2 min, and the supernatant was cytoplasmic fraction and the pellet obtained was mitochondrial fraction which was resuspended in 200 µl buffer A (10 mM Tris-HCl, pH 7.9, 1 mM EDTA, 0.32 M sucrose) and 2 µl 100 mM PMSF.

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For MTT assay, EC-1 and Eca-109 cells were seeded into 96-well plates at a density of 2x10⁴ cells/well and treated with 12 and 20 nM paclitaxel, respectively. Following treatment for 24 h, the cells were collected, washed twice with ice-cold phosphate-buffered saline PBS and subsequently stained with Annexin V-FITC/PI for 20 min by incubation in the dark at room temperature. The samples were then analyzed immediately using a BD Accuri C6 flow cytometer (BD Biosciences).

Reactive oxygen species (ROS) determination. DCFH-DA detection kit was used to measure the intracellular ROS levels according to the manufacturer’s instructions. Briefly, EC-1 and Eca-109 cells were treated with paclitaxel at concentrations of 12 and 20 nM, respectively. Following the treatment for 24 h, cells were collected, washed with RPMI-1640 and incubated with 10 mM DCFH-DA at 37°C for 15 min in the dark. The cells were then washed with RPMI-1640 and resuspended in 200 µl RPMI-1640. The generation of intracellular ROS was analyzed by flow cytometry within 30 min.

JC-1 fluorescence analysis. The MMP was measured by means of JC-1 staining as previously described (24). Briefly, EC-1 and Eca-109 cells treated with paclitaxel were incubated with 2.0 µM JC-1 probe for 20 min at 37°C in the dark. The excess JC-1 probe was removed by washing cells with warm PBS and pelleted by centrifugation. Cell pellets were resuspended in 500 µl PBS and the MMP was assayed by flow cytometry.

RNA interference. EC-1 and Eca-109 cells were transfected with control or STAT3 siRNA (GenePharma, Shanghai, China) using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) in serum-free medium following manufacturer’s instructions. Thirty-six hours post-transfection, cells were seeded on two 6-cm dishes, respectively. Then, cells were treated with or without indicated concentration of PTX (20 nM for EC-1 cells and 12 nM for Eca-109 cells, respectively) for another 24 h. Cells were collected and further subjected to western blot analysis with indicated antibodies. The following sequences for STAT3 siRNA are: STAT3-homo-398 sense, 5’-CCACUUUGUGGUUUCAUAATT3’ and antisense, 5’-UUUAGAAACACCAAGUUGTTT3’; STAT3-homo-978 sense, 5’-GCAACAGAUUGCCGUCAUUTT3’ and antisense, 5’-AUGGAGCAUCAGUUGCTT3’; and control siRNA sense, 5’-UUUCAGCAAGGUGUACUGUTT3’ and antisense, 5’-AGUGGACACUUCCGAGAATT3’.

Western blot analysis. EC-1 and Eca-109 cells were treated with or without paclitaxel for 24 h, then trypsinized and collected in 1.5 ml Eppendorf tubes, lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl) supplemented with protease inhibitor cocktail tablet, NaF (1 mM) and NaN₃ (1 mM) for 15 min on ice and centrifuged at 18,000 g for 20 min at 4°C. Equal amount of protein from total lysates were resolved by 12% SDS-PAGE, the separated proteins were transferred onto nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in Tris-glycine buffer. Blots were blocked at room temperature for 1.5 h in blocking buffer (5% non-fat milk in TBST) on a shaker.
and then incubated overnight at 4°C with primary antibodies as indicated in the figures. After washing, membranes were incubated for 1 h with an anti-mouse or anti-rabbit Ig-HRP and detected with the ECL system. The optical density was quantified by the ImageJ software (National Institutes of Health, Bethesda, MA, USA).

**OXPHOS assay.** The Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) was used to assay mitochondrial bioenergetics by measuring the oxygen consumption rate (OCR). The optimum number of cells was determined to be 20,000/well and incubated in a 37°C 5% CO₂ incubator, and the calibrator plate was equilibrated in a non-CO₂ incubator overnight. Next day, the medium was changed to Dulbecco’s modified Eagle’s medium (unbuffered DMEM, 25 mM glucose, 1 mM glutamine, 1 mM sodium pyruvate) and equilibrated in a 37°C CO₂-free prep station for 40 min. Then, oligomycin (1 µM final concentration), an ATP synthase inhibitor, was injected followed by exposure of carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (1 µM final concentration), an ETC accelerator which causes maximal respiration and finally rotenone plus antimycin A (1 µM final concentration of each) which are mitochondrial complex I and III inhibitors into the cell plate, respectively. EC-1 and Eca-109 cells treated with or without paclitaxel included three replicates and the results were obtained by performing three independent experiments.

**Statistical analysis.** All statistical analyses were carried out using SPSS version 16.0 statistical software package (SPSS Inc., Chicago, IL, USA) and presented with GraphPad Prism version 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). All P-values are two-sided, and p<0.05 was considered a statistically significant difference. Error bars for the experiments represent the standard deviation of the mean value (mean ± SD) from three separate experiments.

**Results**

**Paclitaxel inhibits EC-1 and Eca-109 cell growth and increases intracellular ROS in a time-dependent manner.** The anti-proliferative effect of paclitaxel on EC-1 and Eca-109 cells was determined by performing an MTT assay. We found that paclitaxel treatment reduced the ESCC cell viability in a time-dependent manner (Fig. 1A). In addition, we determined the intracellular ROS production induced by paclitaxel administration.
Paclitaxel treatment, and our results showed that paclitaxel treatment significantly promoted ROS generation in EC-1 and Eca-109 cells (Fig. 1B).

**Paclitaxel induces apoptosis in EC-1 and Eca-109 cells.** We next examined the effect of paclitaxel on apoptosis of ESCC cells. Optical microscopy revealed a significant increase in cell apoptosis (Fig. 2A) and the flow cytometry results showed that apoptotic rates were increased from 2.6 and 0.3% (DMSO control) to 23.5% (p<0.01) and 16.4% (p<0.001) when treated with 12 and 20 nM paclitaxel for 24 h in Eca-109 and EC-1 cells, respectively (Fig. 2B). Additionally, we found that cleaved PARP, cleaved caspase-3, cleaved caspase-7 and cleaved caspase-9 were all markedly increased when Eca-109 and EC-1 cells were treated with paclitaxel (Fig. 2C). Moreover, our results showed that paclitaxel treatment led to increased release of cytochrome c from mitochondria to cytoplasm (Fig. 2D).

Paclitaxel reduces MMP and STAT3 phosphorylation at Ser727 in EC-1 and Eca-109 cells. JC-1 is a membrane-permeable lipophilic dye that exists as J-aggregates in the mitochondrial matrix (red fluorescence) and as monomers in the cytoplasm (green fluorescence). During mitochondrial depolarization, the red J-aggregates form green monomers due to a change in MMP. Thus, depolarization can be measured as an increasing green fluorescent/red fluorescent intensity ratio. Our results showed that paclitaxel causes a significant loss of MMP in EC-1 and Eca-109 cells (Fig. 3A; p<0.1). In addition, we analyzed the protein levels of total and phosphorylated (Ser727) STAT3 in EC-1 and Eca-109 cells by western blot analysis, and our results showed that paclitaxel treatment led to significantly decreased total and phosphorylated (Ser727) STAT3 protein levels (Fig. 3B and C; p<0.05). Moreover, the knockdown of STAT3 in Eca-109 and EC-1 cells enhanced paclitaxel induced PARP and caspase-3 cleavage in Eca-109 and EC-1 cells (Fig. 3D).
Paclitaxel mainly decreases miSTAT3 and phosphorylated (Ser727) STAT3 in EC-1 and Eca-109 cells. STAT3 is also detected in the mitochondria and has functions in regulating glycolysis and OXPHOS of cancer cells. To explore which part of total and phosphorylated (Ser727) STAT3 of EC-1 and Eca-109 cells was reduced after paclitaxel treatment, mitochondrial and cytoplasmic fraction were isolated, and the proteins levels of both total and phosphorylated (Ser727) STAT3 were detected by western blot analysis. Our results showed that paclitaxel treatment reduced total and phosphorylated (Ser727) STAT3 in the mitochondria, but did not decrease the total and phosphorylated (Ser727) STAT3 in the cytosol. GAPDH was used as a cytoplasmic loading control and VDAC was used as a mitochondrial loading control (Fig. 4A). To further clarify the extent of reduction of total and phosphorylated (Ser727) STAT3, we used loading control to normalize total and phosphorylated (Ser727) STAT3 protein level, and the results are statistically significant (Fig. 4B; p<0.05).

Paclitaxel inhibits mitochondrial respiration in EC-1 and Eca-109 cells. Next, we detected the OCR in EC-1 and Eca-109 cells by Seahorse XF96 extracellular flux analyzer. Paclitaxel treatment decreased OCR of EC-1 and Eca-109 cells markedly (Fig. 5A-C). Furthermore, the ATP production was strongly reduced in response to paclitaxel treatment (Fig. 5D), which indicates that paclitaxel treatment may impair the OXPHOS of cancer cells.
Discussion

Paclitaxel is widely used as a common clinical medicine in the treatment of solid tumors (23, 24). In this study, we demonstrated that paclitaxel inhibits the cell viability significantly in both Eca-109 and EC-1 cells through inducing apoptosis of ESCC cells by downregulation of STAT3 Ser727 phosphorylation.

Understanding the mechanism of ROS generation may provide a new method for the development of therapeutic agents that are capable of selectively inducing apoptosis of cancer cells. ROS generation has been shown to be a common cellular mechanism for multiple cell death pathways, including gene activation, cell cycle arrest and apoptosis (21). ROS may also serve as a signal for apoptosis instead of being the consequence of the cellular changes induced by apoptosis (22). ROS generation may alter the redox-state of cells and the sensitivity of cells to apoptotic stimulus and ultimately trigger the subsequent apoptotic events (25-28). Our results showed that paclitaxel treatment resulted in the disruption of MMP,
increased ROS generation, and thus promoted apoptosis in Eca-109 and EC-1 cells.

It has been demonstrated that STAT3 also located in mitochondria (18). In the present study, we found that paclitaxel treatment significantly decreased the total and Ser727 phosphorylated STAT3 level in mitochondria of Eca-109 and EC-1 cells. These results suggest that paclitaxel treatment could reduce the phosphorylation level of STAT3. The reason why total STAT3 changed in paclitaxel-induced ESCC cells is probably associated with the feedback of ESCC cells to paclitaxel treatment as an integrated system.

STAT3 was able to positively regulate the mitochondrial respiration in terminally differentiated cells (29,30) and mtSTAT3 increased the activity of complex I and II in the ETC in a transcriptional-independent manner (18). STAT3 was also linked to carcinogenesis and tumor development shown in previous studies (31-33). Our results indicated that the OCR significantly decreased in paclitaxel-treated Eca-109 and EC-1 cells, which may be attributed to the decrease of mitochondrial respiratory chain enzyme activities. In addition, mitochondrial cytochrome c, which is a downstream regulation factor of STAT3, also significantly increased in the cytosol of both Eca-109 and EC-1 cells, which indicates the loss of MMP caused the leakage of cytochrome c due to the paclitaxel treatment of ESCC cells. It is well known that the increment of ROS level and the decreasing of MMP could reduce the phosphorylation level of STAT3. The reason could be that the increment of ROS level activated STAT3 degradation via proteasomal pathway. Moreover, depletion of STAT3 increased cytochrome c release (28,34,35), the increasing cytochrome c protein level in the cytosol of both Eca-109 and EC-1 cells suggested the paclitaxel-induced mitochondria-dependent apoptotic pathway. Therefore, depletion of STAT3 increased the sensitivity of ESCC cells to paclitaxel through enhancing the cleavage of PARP and caspase-3.

In conclusion, our findings demonstrated that paclitaxel has significant anti-proliferation effects by inducing mitochondrial apoptosis of ESCC cells via STAT3 signaling pathways. Thus, our data provide a novel insight into the mitochondrial apoptosis mechanism of paclitaxel on the ESCC cells in vitro. These findings suggested that paclitaxel may be of therapeutic potential in ESCC treatment through the induction of mitochondrial apoptosis in ESCC cells.

Acknowledgements

The authors would like to thank Dr Sushil Kumar for the critical review of the manuscript. This study was supported by the grant from the National Natural Science Foundation of China (nos. 31171345 and 31570772) to B.L. and the Natural Science Foundation of Zhejiang Province (LY17C070005) to Y.L.

References


